Clinical Trials Logo

Clinical Trial Summary

Mutations in IDH genes are found in numerous cancers and more specifically in acute myeloid leukemia (AML). These mutations target specific amino acids, at positions 140 or 172 of IDH2, and 132 of IDH1. Mutant IDH proteins acquire an abnormal enzymatic activity allowing them to convert α-ketoglutarate (αKG) into D-2 hydroxyglutarate (D-2HG), an oncometabolite which massively accumulates in IDH-mutated cells. At high levels, D-2HG behaves as a competitive inhibitor of αKG and affects the activity of Fe(II)/αKG-dependent dioxygenases. This enzymatic family is involved in a broad spectrum of pathways such as demethylation of histone (JHDM histone demethylases) or DNA (methylcytosine hydroxylases of the TET family). As a result, IDH-mutated cells show altered survival, motility, invasiveness and cell differentiation. In AML, IDH1 mutations might be present in 10-15% at diagnosis Ivosidenib (IVO) a first-in-class, oral, irreversible inhibitor of mutant IDH1 has shown clinical activity as a single agent in studies involving patients with IDH1 mutated relapsed or refractory (R/R) AML and in front line settings. In phase II clinical trials, IVO yielded 30-35% of complete response rates both in frontline and R/R settings, with long lasting responses. Based on these results, the FDA (Food and Drug Agency) gave its approval for newly-diagnosed AML IDH1mut patients who are ≥ 75 years old or who have comorbidities and in R/R. However, European Medicines Agency (EMA)'s did not approved IVO due to lack of evidences to support the application. Agios Netherlands B.V. (the company that previously own the drug before Servier Laboratories) withdrew its EMA application. Nevertheless, IVO has been available in France through a compassionate use program (CUP), since February 2020 for R/R patients and March 2022 for first line treatment. In this multicentric retrospective study, sponsor aim to evaluate the efficacy and safety of Ivo in two cohorts of IDH1mut AML patients treated within the CUP. The first cohort will concern patients treated in first line setting and the second cohort those treated in R/R disease. Results might provide new insights regarding IVO in real life settings and support signs of efficacy. This could provide new data for the haematologist community and for another appliance to grant EMA approval of IVO in the setting of R/R IDH1mut AML.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06377579
Study type Observational [Patient Registry]
Source French Innovative Leukemia Organisation
Contact Ariane MINEUR
Phone +33 (0)5 57 62 31 08
Email ariane.mineur@chu-bordeaux.fr
Status Not yet recruiting
Phase
Start date June 30, 2024
Completion date March 30, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Recruiting NCT06052813 - A Study of BN104 in the Treatment of Acute Leukemia Phase 1/Phase 2
Recruiting NCT06027853 - Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia Phase 1
Completed NCT02986620 - Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
Recruiting NCT05601466 - Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia Phase 1
Recruiting NCT06066905 - A Study of Chidamide With AZA in MRD Positive AML After Transplant N/A
Recruiting NCT05909501 - Assessment of Geriatric Evaluations Impact on New AML Guidance
Terminated NCT04614636 - FT538 in Subjects With Advanced Hematologic Malignancies Phase 1
Not yet recruiting NCT06420063 - Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML Phase 1/Phase 2
Withdrawn NCT04128020 - Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Phase 1
Active, not recruiting NCT04749355 - Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS Phase 2
Active, not recruiting NCT04755244 - A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) Phase 1/Phase 2
Completed NCT03194685 - Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT03884829 - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Phase 1
Active, not recruiting NCT05177731 - Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML Phase 3
Recruiting NCT05025098 - Precision Therapy Versus Standard Therapy in AML and MDS in Elderly Phase 2
Not yet recruiting NCT06263387 - Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
Not yet recruiting NCT06297772 - Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR Phase 3